Molecular glue development continues to thrive, offering exciting opportunities to target previously undruggable proteins and treat a wide range of diseases. 2024 saw a multitude of collaborations, with Takeda and Degron Therapeutics entering a deal worth $1.2 billion.

The 3^rd Molecular Glue Drug Development Summit returned as the only industry-dedicated forum bringing together 90+ experts as they showcased the latest advancements and breakthroughs in molecular glue drug development through discussions and data-driven case studies on screening tools, novel mechanisms of actions of proximity-based degrading and non-degrading molecular glues and lead optimization strategies, to streamline discovery and development of safe and effective glues.